106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved
ASCOMOL19112b
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
genitourinary-cancer-guidelines. Copyright © 2019 by American Society of Clinical Oncolog y. All
rights reserved.
Source
Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular Biomarkers in Localized Prostate
Cancer: ASCO Guideline. J Clin Oncol. 2019 Dec 12 DOI: 10.1200/JCO.19.02768
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/genitourinary-cancer-guidelines.
Abbreviations
DNA, Deoxyribonucleic acid; FFPE, formalin-fixed paraffin-embedded; mRNA, Messenger
RNA; GPS, Genomic Prostate Score; RNA, Ribonucleic acid; RP, radical prostatectomy
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
EP
Expert panel H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
U Unknown Ins Insufficient
